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Abstract:
Background: Hallmarks of the pathogenesis of rotator cuff disease (RCD) include an abnormal immune response, angiogenesis, 
and altered variables of vascularity. Degenerative changes enhance production of pro-inflammatory, anti-inflammatory, and vascular 
angiogenesis-related cytokines (ARC) that play a pivotal role in the immune response to arthroscopic surgery and participate in the 
pathogenesis of RCD. The purpose of this study was to evaluate the ARC profile, ie, interleukin (IL): IL-1β, IL-6, IL-8, IL-10, vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and angiogenin (ANG), in human peripheral blood serum and 
correlate this with early degenerative changes in patients with RCD.
Methods: Blood specimens were obtained from 200 patients with RCD and 200 patients seen in the orthopedic clinic for nonrotator 
cuff disorders. Angiogenesis imaging assays was performed using power Doppler ultrasound to evaluate variables of vascularity in the 
rotator cuff tendons. Expression of ARC was measured by commercial Bio-Plex Precision Pro Human Cytokine Assays.
Results: Baseline concentrations of IL-1β, IL-8, and VEGF was significantly higher in RCD patients than in controls. Significantly higher 
serum VEGF levels were found in 85% of patients with RCD, and correlated with advanced stage of disease (r = 0.75; P , 0.0005), 
average microvascular density (r = 0.68, P , 0.005), and visual analog score (r = 0.75, P , 0.0002) in RCD patients. ANG and IL-10 
levels were significantly lower in RCD patients versus controls. IL-1β and ANG levels were significantly correlated with degenerative 
tendon grade in RCD patients. No difference in IL-6 and bFGF levels was observed between RCD patients and controls. Patients with 
degenerative changes had markedly lower ANG levels compared with controls. Power Doppler ultrasound showed high blood vessel 
density in patients with tendon rupture.
Conclusion: The pathogenesis of RCD is associated with an imbalance between pro-inflammatory, anti-inflammatory, and vascular ARC.
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Introduction
Rotator cuff tear is one of the most common disorders 
in the shoulder joint and causes pain, stiffness, and 
functional disability. Approximately 16% of the gen-
eral population is believed to have rotator cuff disease 
(RCD) at any given time.1 This rises to 21% in elderly 
hospitalized  patients  and  community    populations.2 
The  hallmarks  of  RCD  pathogenesis  include  pro-
inflammatory  and  anti-inflammatory  processes, 
an  abnormal  immune  response,  angiogenesis,  and 
altered  variables  of  vascularity.3 Angiogenesis  is  a 
fundamental process that dominates diseases in many 
branches of medicine and surgery.4 The relationship 
between angiogenesis and degenerative changes in 
RCD patients is attracting increasing attention.
The tendons to supraspinatus, biceps brachii (long 
head), and upper parts of the infraspinatus muscles 
have a zone in which there are no blood vessels, and it 
is in this area that signs of degeneration, including cell 
death,  calcium  deposits,  and  microscopic  ruptures, 
are predominantly located. When blood circulation is 
impaired, such as through compression and static load 
on the shoulder tendons, degeneration can be acceler-
ated because the normal mechanisms for tissue func-
tion will not be optimal. Avascularity is considered to 
be a key factor in the etiology of degenerative   tendon 
disease.5,6  The  capacity  for  repair  after  repetitive 
microtrauma is strongly compromised in the avascular 
tissue of gliding tendons. Reduced vascularity is not a 
specific feature of gliding tendons, and several studies 
have shown that the number and size of blood vessels 
are shortened considerably in the waist of the tendon. 
Angiogenesis is mediated by angiogenic factors, and 
recent studies have shown that vascular endothelial 
growth factor (VEGF) is highly expressed in degen-
erative tendons, whereas VEGF expression is almost 
completely downregulated in healthy tendons. Several 
factors are able to upregulate VEGF expression in teno-
cytes, including hypoxia, inflammatory cytokines, and 
mechanical load. Because VEGF has the potential to 
stimulate the expression of matrix metalloproteinases 
and inhibit the expression of tissue inhibitors of matrix 
metalloproteinases in various cell types (ie, endothe-
lial  cells,  fibroblasts,  chondrocytes),  this  cytokine 
might have a significant role in the pathological pro-
cess of degenerative tendon disease. The neovessels 
are accompanied by small glutamate-positive neural 
structures.  This  finding  suggests  that  angiogenesis 
also plays an important role in the pain associated 
with  degenerative  tendon  disease.  In  the  tendon, 
degenerative changes mostly occur in regions that are 
hypovascular or avascular.   Avascular zones of tendons 
are predisposed to degenerative changes and sponta-
neous rupture in RCD.7   Angiogenesis is mediated by 
angiogenic factors, and recent studies have shown that 
growth factors are highly expressed in degenerative 
tendons.8,9 Alterations  in  vascularity  might  also  be 
involved in the pathogenesis of degenerative tendon 
disease.10
Many extrinsic (impingement, trauma) and intrin-
sic  (degeneration,  inflammation,  hypovascularity) 
factors have been proposed as possible etiologies for 
the wide disparity in progression of RCD between 
individuals. In healthy individuals, the synthesis of 
cytokines in tendons increases in response to physical 
activity, which results in stronger skeletal muscle and 
more resistant connective tissue.11 Cytokines signal 
the normal processes of inflammation and repair in 
all organs, yet the aberrant expression of these pep-
tide  mediators  is  associated  with  significant  organ 
dysfunction. Because cytokines play important roles 
in  cell  chemotaxis,  proliferation,  matrix  synthesis, 
and  cell  differentiation,  these  molecules  have  the 
potential  to  improve  rotator  cuff  tendon  healing.12 
  Angiogenesis-related cytokines (ARC) play an impor-
tant role in initiating the early nonhealing response in 
tendon tissue. ARC and their activity in the early/late 
stages of tendon degeneration are largely unknown. 
Abnormalities in the ARC network of importance in 
the clinical signs and symptoms of RCD will be the 
focus of this paper.
Accurate  and  sensitive  methods  for  measure-
ment and detection of cytokines are important for the 
understanding of cytokine biology and biochemis-
try, and for the assessment of cytokine involvement 
in  pathophysiological  processes.13–15  Various  types 
of  assays  are  available  for  estimation  of  cytokine 
  levels  in  biological  fluids.16  Blood  still  represents 
an ideal clinical source of potential markers because 
of  its  minimally  invasive  and  standardized  acqui-
sition  methods,  and  because  of  its  known  role  in 
reflecting  systemic  changes  associated  with  RCD. 
Serum  and  plasma  are  composed  of  highly  com-
plex  protein/peptide  mixtures  resulting  from  the 
systemic  monitoring  of  every  biological  process 
occurring in a living organism.Biomarkers of early tendon degeneration
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2011:4  45
Changes  in  cytokine  levels  in  peripheral  blood 
serum  are  now  recognized  as  potentially  useful 
markers  of  disease,  indicating  stage,  severity,  and 
  prognosis.  Measurement  of  cytokine  levels  and/or 
soluble markers of immune activation can provide 
reliable  information  in  disease  regarding  diagno-
sis,  staging,  prognosis,  and  evaluation  of  therapy. 
  Serological  methods  for  detecting ARC  as  surro-
gate markers of the processes of neovascularization, 
infection, and inflammation in RCD have great clini-
cal potential, and signal a significant paradigm shift 
in  the  clinical  management  of  orthopedic  disease. 
The quality of laboratory data can impact on their 
clinical relevance. The future of serological mark-
ers, such as ARC in RCD, requires close cooperation 
between  the  public  and  private  sectors,  including 
government, the pharmaceutical and biotechnology 
industries, and academia.
Degenerative changes enhance production of pro-
inflammatory, anti-inflammatory, and vascular ARC 
that play a pivotal role in the immune response to sur-
gical intervention and take part in the pathogenesis of 
RCD.17,18 Investigating the dynamic changes in ARC 
following RCD is important for both understanding 
the pathophysiologic mechanisms of RCD and for 
exploring new methods for therapy, ie, reconstructive 
techniques using angiogenic factors.
The purpose of this study was to evaluate the ARC 
profile, ie, IL-1β, IL-6, IL-8, IL-10, VEGF, bFGF, 
and ANG, in human peripheral blood serum and cor-
relate this with early degenerative changes in patients 
with RCD.
Methods
Patients
The experimental RCD group consisted of  200 patients 
with significant inflammation, tendon degeneration, 
and partial or full thickness rotator cuff tears. Patients 
were followed with clinical measures, ie, (University 
of California, Los Angeles shoulder score, Constant 
score, and Western Ontario Rotator Cuff Index). The 
Constant score19 and visual analog score20 were used 
to perform clinical assessments. The Constant score 
is  based  on  two  subjective  measurements,  ie,  pain 
and the relationship between pain and activities of 
daily living (score, 0–35), and two objective measure-
ments, ie, strength and range of motion as assessed by 
a   physician (score, 0–65). The sum of the two scores 
ranges from 0 (total shoulder impairment) to 100 (non-
impaired shoulder). The visual analog score is a 10 cm 
graduated scale with scores ranging from 0 (no pain) 
to 10 (unbearable pain) whereby patients report the 
score that they believe corresponds to their pain.
The comparative group consisted of 200 patients 
seen  in  the  orthopedic  clinic  for  nonrotator  cuff 
  disorders. Nonrotator cuff disorders include synovial 
disorders (such as adhesive capsulitis and synovial 
osteochondromatosis), degenerative disorders (such 
as osteoarthritis, amyloid arthropathy, hemarthrosis, 
and  chondrocalcinosis),  infectious  disorders  (such 
as septic arthritis and bursitis), and space-occupying 
lesions. All patients with RCD and nonrotator cuff 
disorders  provided  their  written  informed  consent, 
and the study was approved by the ethics commit-
tee of the National Institute of Rehabilitation, Mexico 
City. Patient follow-up information was entered into 
a computerized database.
The control group consisted of 200 age- and sex-
matched healthy individuals with no medical history 
of RCD.
Serum collection
For  the  cytokine  assays,  10  mL  of  venous  blood 
sample was drawn aseptically into Vacutainer® tubes 
(Becton Dickinson, Franklin Lakes, NJ) and imme-
diately  centrifuged  at  3000  rpm  for  10  minutes. 
Thereafter, the serum was separated and aliquoted in 
1.0 mL fractions and stored at −80 °C until the assays 
were performed.
Multiplex assay
A Bio-Plex human cytokine assay for simultaneous 
quantitation of ARC was run according to the recom-
mended procedure. In brief, the premixed standards 
were reconstituted in 0.5 mL of culture medium, gen-
erating a stock concentration of 50,000 pg/mL for 
each cytokine. The standard stock was serially diluted 
in the same culture medium to generate eight points 
for the standard curve. The assay was performed in 
a 96-well filtration plate supplied with the assay kit. 
Premixed beads (50 µL) coated with target capture 
antibodies were transferred to each well of the filter 
plate (5000 beads per well per cytokine) and washed 
twice with Bio-Plex wash buffer. Premixed standards 
or samples (50 µL) were added to each well   containing 
washed beads. The samples were used directly   without Savitskaya et al
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  further dilution. The plate was shaken for 30 seconds 
and then incubated at room temperature for 30 minutes 
with low-speed shaking (300 rpm). After incubation 
and washing, premixed detection antibodies (50 µL, 
final concentration of 2 µg/mL) were added to each 
well. The incubation was terminated after shaking for 
10 minutes at room   temperature. After three washes, 
the beads were resuspended in 125 µL of Bio-Plex 
assay buffer. Beads were read on the Bio-Plex suspen-
sion array system, and the data were analyzed using 
Bio-Plex Manager™ software (version 3.0) with 5PL 
curve fitting.
Standards and control
The ARC  was  measured  using  commercial  immu-
noassays, ie, the Bio-Plex human cytokine assay kit 
(Bio-Rad Inc, Hercules, CA) as per the   manufacturer’s 
instructions,  the  International  Standards  of  the 
National Institute for Biological Standards and Con-
trol, and the recommendations of the Expert Commit-
tee on Biological Standardization of the World Health 
Organization for cytokine measurements. All samples 
were masked for subject identity and analyzed using 
a standard range of 0–3200 pg/mL and a sample dilu-
tion of 1:4, as recommended by the manufacturer.
Purification of human ARC
Serum samples donated by normal human volunteers 
and RCD patients were collected through the Blood 
Transfusion  Service  of  the  National  Institute  of 
Rehabilitation. Human ARC was purified in an ARC 
affinity  column  (Amersham  Pharmacia  Biotech, 
Piscataway,  NJ)  and  AKTAFPLC  (Amersham 
Pharmacia  Biotech).  Procedures  were  carried  out 
according to the manufacturer’s instructions. Briefly, 
serum samples were first prepared with ammonium 
sulfate until the final concentration was 0.8 M. The 
prepared sera were applied to the affinity column which 
had been precalibrated. ARC affinity binding buffer 
[20 nM sodium phosphate and 0.8 M (NH4)2SO4, pH 
7.5] was then applied to wash out unbound factors; 
bound ARC was eluted by 20 nM sodium phosphate, 
pH 7.5. The flow rate of the overall purification pro-
cedure was 1 mL/min.
Specimen preparation
Rotator cuff samples were immediately fixed in 4% 
formaldehyde  for  24  hours,  dehydrated  in  graded 
alcohol solution and cedarwood oil, and   embedded 
in  paraffin.  Sections  were  cut  at  5  µm  with  a 
RM2055  microtome  (Leica,  Bensheim,  Germany) 
40  °C  stainless  steel  knife.  Standard  histological 
staining  was  performed  using  a  Masson-Goldner 
staining kit (Merck, Darmstadt, Germany) according 
to the manufacturer’s instructions.
histology
Histological  analysis  was  performed  at  a  primary 
objective  lens  magnification  of  5×  using  a  Leica 
DM5000  and  Quips  analysis  software  (Leica). 
  Biopsies of the superficial part of the supraspinatus 
tendon in patients with RCD were analyzed using his-
tological techniques.
Ultrasound imaging
Ultrasound imaging studies were performed on each 
shoulder. All scans were performed using a Siemens 
Acuson  Antares  (Siemens,  Erlangen,  Germany) 
machine with a 7.5–15 mHz linear array transducer. 
The  shoulder  scoring  system  assessed  elements  of 
inflammation, as well as structural tendinous and bony 
damage. Rotator cuff tendons were investigated for 
the presence of total or partial tears in the longitudinal 
and transverse planes in static and dynamic positions. 
The  synovial  structures  of  the  shoulder,  including 
the subacromial-subdeltoid bursa, sheath of the long 
biceps tendon, and axillary and posterior recess of the 
glenohumeral joint, were examined for the presence 
of effusions and synovial hypertrophy. The humeral 
head  was  examined  for  the  presence  of  erosions. 
Power Doppler assessment of selected synovial sites, 
including the biceps sheath, subacromial-subdeltoid 
bursa, and axillary and posterior recesses was carried 
out with settings standardized to a pulse repetition 
frequency of 400–500 Hz and low wall   filters. The 
power Doppler gain was adjusted to a level just below 
the disappearance of color signs under the bony cor-
tex  as  recommended  by  Rubin  et  al.    OMERACT 
(Outcome Measures in Rheumatoid Arthritis Clini-
cal  Trials)  definitions  for  joint  effusion,  synovial 
hypertrophy, tenosynovitis, and bone erosions were 
adhered to. The following definitions for the clas-
sification  of  ultrasonographic  findings  were  used: 
cortical irregularities .2 mm were considered as ero-
sions; a hypoechoic area of at least .3 mm around 
the long head of the biceps tendon as tenosynovitis Biomarkers of early tendon degeneration
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of the long biceps tendon; bursal   thickness .3 mm or 
effusion as effusion/synovial hypertrophy of the sub-
acromial-subdeltoid bursa; .3 mm effusion/synovial 
hypertrophy at the posterior recess superior to the gle-
noid labrum as synovitis; and .3 mm effusion/syn-
ovial hypertrophy at the axillary recess as synovitis. 
No ultrasonographic distinction was made between 
effusions and synovial hypertrophy, and these abnor-
malities were taken together for the analyses.
Magnetic resonance imaging
Magnetic  resonance  imaging  studies  (MRI)  were 
performed  on  each  shoulder.  Assessment  of 
the affected shoulder by MRI took place within five 
working days prior to the ultrasound investigation 
in all patients. MRI was performed with a 1.5-T 
unit  (Signa  Excite,  General  Electric,  Milwaukee, 
WI) using a flexible wraparound coil. The follow-
ing  sequences  were  used:  T1-weighted  fast  spin 
echo sequence with repetition time of 500 msec, 
echo time of 13.6 msec, slice thickness of 4 mm, 
and  fields  of  view  of  140–160  mm  in  the  axial, 
transverse,  and  oblique  coronal  slice  orientations 
parallel to the course of the tendon of the supraspi-
natus;  T2-weighted  fat-suppressed  images  in  the 
coronal and sagittal planes with a repetition time of 
3300 msec and an echo time of 71 msec. After selec-
tion of a suitable slice in which abnormal changes 
were  visualized,  a  dynamic  contrast-  enhanced 
study  with  intravenous  injection  of  gadolinium 
diethylenetriaminepentaacetic  acid  0.1  mmol/kg 
body weight was performed using axial and coro-
nal T1-weighted (repetition time 500 msec, echo 
time 13.6 msec, and fields of view of 140–160 mm) 
fat-suppressed  sequences  T1-weighted  and  coro-
nal  oblique  contrast-enhanced  fat-suppressed 
T1-weighted sequences were performed. The MRI 
scans were evaluated by two radiologists who were 
in agreement and had no knowledge of the results of 
ultrasonography. The MRI scans were analyzed for 
the presence or absence of the same structures that 
were visualized by ultrasonography. The MRI crite-
rion for effusion was an intra-articular or intrabursal 
area with a high signal on T2-weighted sequences 
without  contrast  enhancement  on  fat-suppressed 
T1-weighted sequences. The criterion for synovitis 
was enhancing signals seen on the fat-suppressed 
T1-weighted sequences.
Statistical analysis
Statistical  analyses  were  done  using  the Wilcoxon 
rank  sum  test  without  any  assumption  about  the 
distribution  of  data.  Standard  statistical  software 
(SAS 6.12 version, SAS Inc, Cary, NC) was used 
for all statistical analyses. Data are reported as the 
means ± standard error of measurements. Statistical 
significance was defined as P , 0.05.
Results
Patient characteristics
The baseline characteristics of the study RCD patients 
are shown in Table 1.
ARC profiles
Following the Bio-Plex assay procedure, we examined 
variations in ARC levels in the sera from controls and 
RCD patients (Table 2). ARC were detected using the 
Bio-Plex assay in the sera of RCD patients, as well 
as in the sera of controls (Figs. 1–3). IL-1β, IL-8, 
and VEGF levels were significantly higher in RCD 
patients than in controls. Serum ANG and IL-10 levels 
were significantly lower in RCD patients than in con-
trols. Serum IL-10 levels are a diagnostic indicator of 
the anti-inflammatory phase. The anti-inflammatory 
action  of  this  cytokine  consists  of  inhibition  of 
inflammatory mediators, such as IL-6 and IL-8. Anti-
inflammatory  IL-10  exerts  a  protective  effect,  but 
protection is incomplete. Patients with degenerative 
changes  had  considerably  lower  serum  angiogenin 
levels compared with controls. A combination of high 
VEGF and low ANG concentrations in the sera have 
been considered as a predisposing factor for patients 
Table 1. Baseline characteristics.
RcD  
patients
controls
characteristic
Patients (n) 200 200
Mean (SD) age (years) 40.3 ± 10.9 43.3 ± 11.5
range (years) 29–72 31–75
Male 112 107
Female 88 93
Mean (SD) height mass (kg) 169.0 ± 9.1 161.2 ± 10.2
Mean (SD) body mass (kg) 79.1 ± 13.5 74.9 ± 11.8
Mean (SD) body mass  
index (kg/m2)
27.8 ± 4.4 26.4 ± 5.1
Abbreviations: rCD, rotator cuff disease; SD, standard deviation.Savitskaya et al
48  Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2011:4
Normal
tendon
Significant
inflammatory
Degenerate  Rupture
IL-1beta
IL-10
IL-8
IL-6 30
40
50
0
10
20
Figure 1. Pro-/anti-inflammatory ARC in RCD.
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Figure 3. ARC profiles of tendon.
Table 2. Angiogenesis-related cytokine expression.
ARc  
(pg/mL)
The control  
group
The 
comparative  
group
RcD patients
Significant  
inflammatory
Degenerative Ruptured
Pro-inflammatory ARC
Local inflammatory
IL-1 3.33 ± 0.69 5.21 ± 1.10 16.17 ± 6.71 38.52 ± 10.32 43.71 ± 8.91
IL-6 5.37 ± 0.93 6.11 ± 0.87 10.45 ± 2.92 18.21 ± 0.71 25.11 ± 3.11
Chronic inflammatory
IL-8 9.11 ± 0.98 9.78 ± 2.31 15.31 ± 0.85 22.41 ± 0.92 27.81 ± 1.11
Anti-inflammatory ARC
IL-10 9.53 ± 1.21 10.21 ± 1.45 7.64 ± 1.11 5.15 ± 0.65 3.11 ± 1.91
Vascular ARc
VegF 339.67 ± 74.65 349.21 ± 55.78 402.11 ± 88.11 598.03 ± 298.25 621.24 ± 301.11
bFgF 8.14 ± 2.91 7.54 ± 1.84 12.34 ± 2.37 16.82 ± 3.41 19.91 ± 5.24
Ang 239.51 ± 58.4 265.21 ± 77.11 166.45 ± 44.90 111.31 ± 34.21 89.39 ± 40.19
Abbreviations: ANG, angiogenin; ARC, angiogenesis-related cytokines; bFGF, basic fibroblast growth factor; IL, interleukin; RCD, rotator cuff disease; 
VegF, vascular endothelial growth factor.
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Figure 2. Vascular ArC in rCD.
with ruptures of rotator cuff tendons. No difference in 
bFGF levels was observed between RCD patients and 
controls. Levels of IL-1β and angiogenin were sig-
nificantly correlated with degenerative tendon grade 
in RCD patients.
Correlations
We examined the affected shoulder with ultrasound 
according  to  guidelines  issued  by  the  European 
  Society  of  Musculoskeletal  Radiology.21  For  each 
patient,  the  tendon  was  recorded  (Fig.  4).  Power 
  Doppler ultrasound examination revealed high blood 
vessel   density in patients with tendon ruptures.5 We 
found a significant correlation between power   Doppler 
ultrasound  and  VEGF  expression  in  patients  with 
RCD and controls. There was a significant correlation 
between vessel density and VEGF (Figs. 5 and 6). 
Overexpression of VEGF correlated with advanced 
disease (r = 0.75; P , 0.0005), average microvascular 
density (r = 0.68, P , 0.005), and visual analog score 
(r = 0.75, P , 0.0002) in patients with RCD. We 
found a correlation between VEGF and IL-8 in the 
sera of patients with RCD (Table 3).
Vascularity
Histological biopsies from degenerative tendons and 
Doppler  flow  examinations  revealed  a  high  blood 
vessel density in patients with degenerative tendon 
disease. Figure 7 shows examples for different tendon 
sections  and  staining. Vascularity  analyses  support Biomarkers of early tendon degeneration
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A
B
Figure  4.  Ultrasound  appearance  of  a  normal  and  a  degenerative 
supraspinatus tendon. panel A) Transverse scan: Normal fibrillar pattern 
and thickness of Supraspinatus Tendon is observed (between calipers). 
panel B) Supraspinatus tendon is thickened (calipers), hypoechoic, non-
homogeneous, with loss of the normal fibrillar pattern. In this picture, an 
effusion in the subacromial bursa is present*. 1 supraspinatus tendon, 
2 biceps tendon, h humeral head and D deltoid muscle.
impingement, while others suspect a primary process 
of  tendon  degeneration.31,32  In  a  recent  literature 
review,  Nho  et  al  concluded  that  hypovascularity 
contributes minimally to cuff tears, which supports 
our finding that hypervascularization occurs late in 
the course of rotator cuff tendinopathy.14,33–35
Cytokine and chemokine networks play a key role 
in the pathogenesis of RCD. Several cytokines are 
expressed in tissues from primary frozen shoulders. 
However, little research has been done to investigate 
the molecular mechanism and cytokine expression in 
rotator cuff lesions with shoulder stiffness. Therefore, 
we hypothesized that shoulder pain and joint stiffness 
in RCD is caused by the ARC network. Therefore, 
the present study focused on ARC expression and its 
relationship to clinical features in patients with RCD.
This  study  evaluated ARC  concentrations  exten-
sively, correlated these with degenerative tendons in 
RCD, provides a novel standardized analytic approach 
for assessing changes in ARC levels, and may improve 
strategies  for  monitoring  the  immune  response  in 
patients  with  RCD. We  used  the  Bio-Plex  assay  to 
determine ARC responses in RCD patients successfully, 
showing that it can be used for serological diagnosis of 
RCD and as a basis for further laboratory tests.
Our  results  suggest  a  significant  role  for  ARC 
in the development of RCD. Most patients present 
a  typical  course  of  inflammatory  response,  which 
runs in two phases, ie, pro-inflammatory and anti-
  inflammatory. Increased serum levels of cytokines, 
including  IL-1β,  IL-6,  and  IL-8  in  RCD  patients 
are  a  diagnostic  indicator  of  the  inflammatory 
phase. IL-8 is one of the most important inflamma-
tion markers. Its pro-inflammatory activity is asso-
ciated with stimulation of lymphocytes B and T, as 
well  as  mesangial  cell  proliferation.36  In  the  pres-
ent study, a significant increase in serum IL-1β and 
IL-8 levels was demonstrated in RCD patients. The 
IL-6 level was also higher in RCD patients. Ko et al 
demonstrated that expression of IL-8 in joint fluid 
from patients with rotator cuff tears and stiffness was 
higher than that from patients with rotator cuff tears 
without    shoulder  stiffness. As  for  IL-8  expression, 
our findings are consistent with those of Ko et al, but 
also indicate that the levels of IL-1β and TNF-α in 
joint fluid are higher in patients with stiffness. In our 
study, there was no significant difference in IL-6 level 
between RCD patients and controls.
our  hypothesis  that  tendon  degeneration  is  closely 
associated with abnormalities in angiogenesis.
Discussion
The applications for biomarkers is a growing field, 
particularly in RCD.22–24 Combining markers is intui-
tively the next step for a number of reasons, and is 
a strategy being adopted in a number of fields, not 
just  in  biomarkers,  and  it  makes  good  financial 
as well as scientific sense to use what has already 
been   identified.25 Biomarkers have a number of uses, 
eg, selection of participants in drug trials, and for early 
diagnosis, prognosis, and assessment of response to 
treatment. Because of the chronic and variable nature 
of RCD, new methods are needed to optimize the 
selection of patients for trials and as outcome mea-
sures, in short, any route by which the chronic course 
of RCD can be shortened into a more cost-effective 
time frame.
The etiology of RCD is still not entirely understood. 
Tendons  are  metabolically  active  tissues  requiring 
a blood supply,26 compromise of which may cause 
degeneration.27,28 Tendon vascularization is the most 
important factor in the pathogenesis of RCD.29,30 Some 
authors ascribe mechanical damage to subacromial Savitskaya et al
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Increased  serum  IL-10  is  also  a  diagnostic 
indicator  of  the  anti-inflammatory  phase.37  The 
anti-  inflammatory  action  of  this  cytokine  con-
sists  of  inhibition  of  inflammatory  mediators, 
including IL-6 and IL-8. Furthermore, IL-10 stops 
the  synthesis  of  tumor  necrosis  factor  alpha  and 
reduces the effector functions of both monocytes 
and natural killer cells.38 An intensified anti-inflam-
matory phase of the inflammatory response in RCD 
patients may be protective against the development 
of a significant inflammatory stage. In this study, 
our  patients  had  low  serum  IL-10  levels  during 
development of RCD.
Neovascularization  in  rotator  cuff  and  tendon 
tissues is mediated by vascular ARC. While VEGF-
  mediated  angiogenesis  contributes  to  repair  and 
remodeling  of  degenerative  tendons,  invasion  by 
endothelial  cells  may  also  weaken  the  mechani-
cal  stability  of  the  tendon.10,39,40  We  assume  that 
increasing vessel density weakens the tendons due 
to the accretive nature of tendon retraction. This has 
been supported by the recently published theoreti-
cal model of Peers et al, showing that chronic ten-
don loading causes mechanical trauma, with multiple 
microruptures  of  the  tendon  microvasculature.18,41 
These  microruptures  initiate  a  VEGF-mediated 
cascade  of  vascular  remodeling  that  becomes 
chronically  pathological.42,43    Hypervascularity  has 
been demonstrated in degenerative human and rabbit 
Achilles tendons, and in diseased patellae and long 
head of biceps tendons.44,45 Chronic tendon pathol-
ogy appears to be a highly active process of ongoing 
neovascularization.46,47  VEGF  expression  and  neo-
vascularization could be used in the clinical setting 
to monitor tendon degeneration in patients with rota-
tor cuff injuries. A hypervascularized zone has been 
identified in the rotator cuff, and coincides with the 
most common location for tears.17,26,48,49 Our findings 
are supported by studies showing increased Doppler 
flow  in  RCD,  likely  reflecting  a  revascularization 
process.
RCD causes considerable shoulder pain, and this 
is  one  of  the  most  uncomfortable  symptoms  for 
patients.  An  inflammatory  ARC  condition  might 
be responsible for the shoulder pain, although the 
relationship between ARC and the pain of a cuff 
tear has received little attention in previous reports. 
Our data indicate a correlation between VEGF lev-
els and visual   analog score. Thus, as for the VEGF 
concentration in the affected shoulder joint, there 
might be a relationship to the shoulder pain of RCD 
patients.
Our  data  demonstrate  that  the  use  of  a  mul-
tiple ARC assay platform is suitable for identifying 
distinct  ARC  profiles  associated  with  the  clinical 
manifestations and severity of RCD. The pathogenesis 
of  RCD  is  associated  with  an  imbalance  between 
pro-inflammatory,  anti-inflammatory,  and  vascular 
cytokines. The  dynamic  changes  in ARC  levels  in 
patients with RCD suggest that angiogenesis factors 
might play a role in the pathogenesis of RCD, such 
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Figure 5. Baseline long-axis power Doppler ultrasound image of supraspi-
natus tendon shows two peribursal vessels and no intratendinous vessels. 
Low level of background noise (color) is evident. The large vessels (far 
left) were persistent findings when observed in real time. The remaining 
tiny flecks of orange, likely representing noise, were inconsistent during 
real-time observation. redder hues correspond to greater intensity of the 
Doppler signal.
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Figure 6. relationship between vasular endothelial growth factor concen-
trations, measured at first presentation in a cohort of patients with early 
rotator cuff disease, and tendon damage over the following year, expressed 
as change in the Van der Heijde modification of the Sharp score.Biomarkers of early tendon degeneration
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that  RCD  disorders  could  be  classified  together  as 
“angiogenesis-dependent diseases”. ARC expression 
in the serum of patients with RCD may provide useful 
prognostic  information  for  orthopedic  surgeons. 
Moreover,  assessment  of  an ARC  panel  may  help 
monitor  rehabilitation  after  arthroscopic  RCD,  and 
assist in future planning of treatment and/or surgical 
intervention.
Measurement of ARC levels can provide reliable 
information regarding diagnosis, staging, prognosis, 
and evaluation of therapy. However, methodological 
difficulties and inaccuracies have been reported, and 
a number of factors have been shown to affect the 
validity  and  quality  of  such  measurements.50  Bio-
Plex assays are the most widely used measurement 
technique,  although  pitfalls  and  limitations  are 
known. Differences in levels of measured analytes 
for  identical  samples  in  the  range  of  10–100-fold 
have been reported.51 Thus, much research, including 
international collaborative studies organized by the 
World  Health  Organization  for  standardization  of 
cytokine measurements, have been conducted.
conclusion
The Bio-Plex assay is the measurement of choice for 
endogenous ARC levels in biologic fluids, and normal 
ranges for cytokines must be established if they are to 
have clinical applications in the future. ARC play an 
important role in initiating the early response to tendon 
degeneration. The role of ARC in the pathogenesis of 
RCD creates an imbalance between degeneration and 
repair. Early tendon degeneration is ARC-mediated. 
Degenerative changes enhance production of pro-in-
flammatory, anti-inflammatory, and vascular ARC that 
play a pivotal role in the immune response. The dis-
covery of the importance of IL-8, IL-10, VEGF, and 
angiogenin in the pathogenesis of RCD has greatly 
altered views about the role of ARC in RCD.
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